Your browser is no longer supported. Please, upgrade your browser.
Settings
MGNX [NASD]
MacroGenics, Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own0.50% Shs Outstand56.24M Perf Week13.83%
Market Cap2.07B Forward P/E- EPS next Y-2.23 Insider Trans-13.56% Shs Float53.31M Perf Month10.47%
Income-129.70M PEG- EPS next Q-0.60 Inst Own90.90% Short Float5.88% Perf Quarter51.86%
Sales104.90M P/S19.71 EPS this Y21.60% Inst Trans-0.11% Short Ratio4.00 Perf Half Y37.89%
Book/sh5.26 P/B6.40 EPS next Y-30.40% ROA-38.60% Target Price33.70 Perf Year380.86%
Cash/sh4.44 P/C7.59 EPS next 5Y- ROE-50.60% 52W Range6.20 - 33.61 Perf YTD47.24%
Dividend- P/FCF- EPS past 5Y-31.30% ROI-44.30% 52W High0.15% Beta2.27
Dividend %- Quick Ratio6.20 Sales past 5Y0.80% Gross Margin- 52W Low442.63% ATR1.89
Employees370 Current Ratio6.20 Sales Q/Q109.10% Oper. Margin- RSI (14)62.93 Volatility6.86% 6.27%
OptionableYes Debt/Eq0.00 EPS Q/Q94.00% Profit Margin- Rel Volume1.23 Prev Close31.87
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume784.51K Price33.66
Recom1.80 SMA206.59% SMA5023.47% SMA20033.27% Volume957,443 Change5.62%
Mar-12-21Upgrade Barclays Underweight → Overweight $14 → $40
Dec-22-20Resumed H.C. Wainwright Buy $36
Aug-03-20Downgrade Citigroup Buy → Neutral $25 → $26
Jun-01-20Upgrade Guggenheim Neutral → Buy
May-26-20Reiterated H.C. Wainwright Buy $22 → $40
Mar-04-20Initiated Barclays Underweight $8
Dec-19-19Initiated Cantor Fitzgerald Overweight
Dec-18-19Initiated Cantor Fitzgerald Overweight
Nov-21-19Downgrade Morgan Stanley Equal-Weight → Underweight $17 → $6
Nov-20-19Resumed Guggenheim Neutral
May-03-19Upgrade Wedbush Neutral → Outperform $26
Apr-12-19Initiated Guggenheim Neutral
Feb-07-19Upgrade Citigroup Sell → Buy
Feb-07-19Downgrade Wedbush Outperform → Neutral
Feb-06-19Upgrade Raymond James Underperform → Mkt Perform
Feb-04-19Downgrade Citigroup Neutral → Sell $10
Dec-10-18Downgrade Raymond James Outperform → Underperform
Sep-10-18Resumed BTIG Research Buy $30
May-31-18Initiated Evercore ISI Outperform $33
Mar-05-18Initiated H.C. Wainwright Buy $38
Apr-19-21 04:30PM  
Apr-10-21 08:30AM  
Apr-09-21 06:30AM  
Mar-15-21 03:15AM  
Mar-02-21 11:43PM  
Feb-26-21 07:30AM  
01:31AM  
Feb-25-21 04:01PM  
02:30PM  
Feb-18-21 04:30PM  
Feb-11-21 04:30PM  
07:30AM  
Feb-08-21 07:30AM  
Jan-25-21 03:34PM  
07:30AM  
Jan-11-21 08:45AM  
Dec-22-20 11:52PM  
11:35AM  
Dec-18-20 07:30AM  
Dec-17-20 03:47PM  
08:10AM  
Dec-16-20 08:15PM  
04:30PM  
Dec-13-20 09:14AM  
Dec-07-20 07:30AM  
Dec-06-20 01:00PM  
Dec-01-20 08:08AM  
Nov-30-20 04:30PM  
07:30AM  
Nov-09-20 05:00PM  
Nov-06-20 08:06AM  
Nov-05-20 04:33AM  
Nov-04-20 06:05PM  
04:27PM  
04:01PM  
02:30PM  
02:30PM  
Oct-28-20 04:30PM  
12:32PM  
Oct-15-20 04:30PM  
Oct-05-20 11:19AM  
Sep-23-20 07:15AM  
Sep-22-20 04:30PM  
Sep-21-20 07:30AM  
Sep-20-20 09:10AM  
Sep-16-20 10:37AM  
Sep-03-20 07:30AM  
Aug-05-20 04:30PM  
Aug-02-20 10:21AM  
Aug-01-20 03:03AM  
Jul-31-20 06:55AM  
Jul-30-20 06:40PM  
04:01PM  
Jul-23-20 07:30AM  
Jul-22-20 12:32PM  
Jul-09-20 06:43PM  
05:22PM  
Jun-27-20 09:28PM  
Jun-22-20 09:00AM  
Jun-16-20 07:30AM  
Jun-05-20 07:30AM  
Jun-03-20 04:05PM  
May-29-20 12:45PM  
May-28-20 07:30AM  
May-27-20 07:30AM  
03:50AM  
May-21-20 04:05PM  
May-18-20 07:06AM  
May-13-20 05:10PM  
May-12-20 08:40AM  
May-11-20 04:37PM  
11:14AM  
06:29AM  
May-08-20 08:10AM  
07:34AM  
May-06-20 03:01PM  
01:24PM  
May-05-20 06:45PM  
04:01PM  
08:36AM  
Apr-29-20 04:01PM  
Apr-28-20 04:01PM  
07:30AM  
Apr-27-20 12:05AM  
Apr-20-20 09:01AM  
Apr-17-20 08:54AM  
Mar-16-20 06:16PM  
Mar-10-20 01:50AM  
Mar-04-20 05:00PM  
Mar-02-20 08:45AM  
Feb-27-20 10:30AM  
07:30AM  
Feb-25-20 04:01PM  
Feb-24-20 02:48PM  
Feb-13-20 07:30AM  
Feb-10-20 07:30AM  
Jan-14-20 03:12PM  
Jan-13-20 07:30AM  
Jan-09-20 04:30PM  
Jan-06-20 05:14PM  
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B A CD79B DART molecule for the treatment of autoimmune indications. MacroGenics, Inc. has strategic collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Spitznagel ThomasSr VP, BPD & ManufacturingApr 15Option Exercise7.515,00037,5505,000Apr 19 06:37 PM
Spitznagel ThomasSr VP, BPD & ManufacturingApr 15Sale30.915,000154,5500Apr 19 06:37 PM
Karrels JamesSVP, CFO and SecretaryMar 22Sale33.0015,000495,000143,460Mar 24 05:07 PM
Bonvini EzioSr VP, Research & CSOMar 22Sale32.003,917125,34479,890Mar 24 05:04 PM
Peters Jeffrey StuartGeneral CounselMar 08Option Exercise11.5021,749250,11421,749Mar 09 07:55 PM
Peters Jeffrey StuartGeneral CounselMar 08Sale26.5021,749576,3480Mar 09 07:55 PM
Karrels JamesSVP, CFO and SecretaryJan 28Option Exercise1.426,0008,490158,460Jan 29 05:10 PM
Risser Eric BlasiusSr VP & Chief Business OfficerDec 29Option Exercise1.5150075544,968Dec 30 04:05 PM
Risser Eric BlasiusSr VP & Chief Business OfficerDec 29Sale24.1050012,05044,468Dec 30 04:05 PM
Risser Eric BlasiusSr VP & Chief Business OfficerNov 30Option Exercise1.5150075544,968Dec 01 04:15 PM
Risser Eric BlasiusSr VP & Chief Business OfficerNov 30Sale23.3550011,67544,468Dec 01 04:15 PM
Risser Eric BlasiusSr VP & Chief Business OfficerOct 28Option Exercise1.511,5002,26545,968Oct 29 07:52 PM
Risser Eric BlasiusSr VP & Chief Business OfficerOct 28Sale20.691,50031,03544,468Oct 29 07:52 PM
Risser Eric BlasiusSr VP & Chief Business OfficerSep 28Option Exercise1.5150075544,968Sep 29 04:44 PM
Risser Eric BlasiusSr VP & Chief Business OfficerSep 28Sale25.3350012,66544,468Sep 29 04:44 PM
Bonvini EzioSr VP, Research & CSOSep 18Sale32.0018,339586,84883,807Sep 21 04:51 PM
Bonvini EzioSr VP, Research & CSOSep 17Sale29.8844,5121,330,019102,146Sep 21 04:51 PM
Galbraith KennethDirectorSep 09Option Exercise17.3820,773361,10313,849Sep 10 04:44 PM
Galbraith KennethDirectorSep 09Sale27.1120,773563,1560Sep 10 04:44 PM
Spitznagel ThomasSr VP, BPD & ManufacturingAug 20Option Exercise7.517,50056,3257,500Aug 21 04:05 PM
Spitznagel ThomasSr VP, BPD & ManufacturingAug 20Sale26.877,500201,5250Aug 21 04:05 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJul 27Option Exercise1.454,4896,50048,468Jul 28 05:12 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJul 27Sale25.474,489114,31944,468Jul 28 05:12 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJul 02Option Exercise1.513,1004,68147,568Jul 06 04:25 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJul 02Sale30.003,10093,00044,468Jul 06 04:25 PM
Peters Jeffrey StuartGeneral CounselJul 02Sale30.002026,0600Jul 06 04:25 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJun 24Option Exercise0.9450047044,968Jun 25 04:57 PM
Risser Eric BlasiusSr VP & Chief Business OfficerJun 24Sale28.4950014,24544,468Jun 25 04:57 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 26Option Exercise0.9450047044,968May 27 04:43 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 26Sale26.5950013,29544,468May 27 04:43 PM
Spitznagel ThomasSr VP, BPD & ManufacturingMay 20Option Exercise7.517,50056,3257,500May 21 07:44 PM
Spitznagel ThomasSr VP, BPD & ManufacturingMay 20Sale25.307,500189,7500May 21 07:44 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 06Option Exercise1.478,03211,84352,500May 07 04:22 PM
Risser Eric BlasiusSr VP & Chief Business OfficerMay 06Sale20.958,032168,30044,468May 07 04:22 PM